<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03626714</url>
  </required_header>
  <id_info>
    <org_study_id>RTB-010</org_study_id>
    <secondary_id>U44AI069674</secondary_id>
    <nct_id>NCT03626714</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study</brief_title>
  <official_title>An Open-Label, First-in-human, Safety and Pharmacokinetic Study of 1-Month Sustained-Release Injectable Tacrolimus in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auritec Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Auritec Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human study is designed to assess the safety and pharmacokinetic (PK) profile
      of sustained-release (SR) depot tacrolimus, which will be administered as a single dose of
      0.1 mg/kg by subcutaneous (SC) injection in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human study to assess the safety and pharmacokinetic (PK) profile of
      sustained-release (SR) tacrolimus, which will be administered as a single dose of 0.1 mg/kg
      by subcutaneous (SC) injection in healthy subjects.

      The short-term general investigational plan is to evaluate sustained release tacrolimus in
      healthy volunteers for up to 30 days in an exploratory trial to determine safety and drug
      concentrations in blood. The results from this study will inform the long-term goal of this
      program, which is to provide an improved treatment modality for prophylaxis of organ (kidney,
      liver and heart) transplant rejection with the additional benefit of enhancing medication
      compliance. These improvements have the potential to mitigate both the personal and economic
      burden of this disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Actual">January 5, 2019</completion_date>
  <primary_completion_date type="Actual">January 5, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects That Experienced Treatment-related Adverse Events [Safety and Tolerability]</measure>
    <time_frame>60 days</time_frame>
    <description>Adverse events were documented at each study visit according to the criteria set forth in the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials as follows:
Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Concentrations in Blood Samples at Individual Time-points</measure>
    <time_frame>60 days</time_frame>
    <description>The concentrations of tacrolimus in blood samples were measured at baseline, day 1 (1 hr, 3 hrs, 6 hrs, 12 hrs, and 24 hrs), followed by days 3, 7, 14, 21, 30, 37, 44, 51 and 60.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Blood Concentration-time Curve - Cmax</measure>
    <time_frame>60 days</time_frame>
    <description>Maximum observed tacrolimus whole blood concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Blood Concentration-time Curve - Tmax</measure>
    <time_frame>60 days</time_frame>
    <description>Time to maximum observed tacrolimus whole blood concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Concentration-time Curve [AUC]</measure>
    <time_frame>60 days</time_frame>
    <description>Area under the concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life [t1/2]</measure>
    <time_frame>60 days</time_frame>
    <description>The apparent terminal elimination half-life was calculated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Organ Transplant Rejection</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Sustained Release Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be treated with a single dose injection of sustained-release Tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustained Release Injectable Tacrolimus</intervention_name>
    <description>Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.</description>
    <arm_group_label>Sustained Release Tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be able to understand and provide informed consent. A signed informed
             consent form must be provided before any study assessments are done;

          -  Males or females, between 18 and 45 years of age, inclusive;

          -  Body mass index must be within the range 18.5 to 32.0 kg/m2, inclusive;

          -  Must be in good health, as determined by no clinically significant findings from
             medical history, vital signs, and 12-lead electrocardiogram (ECG), inclusive of
             documented absence of QT prolongation;

          -  Clinical laboratory evaluations (including clinical chemistry panel [fasted at least
             10 hours], complete blood count [CBC], and urinalysis [UA]) must be within the
             reference range for the test laboratory, unless deemed not clinically significant by
             the Investigator;

          -  Must be negative for autoimmune disorders in the past 3 months and at Screening -
             participant's medical history will be used for this evaluation;

          -  Must not use any immunosuppressant calcineurin inhibitor product other than SR
             Injectable tacrolimus throughout the dosing period and until after the final visit;

          -  Must agree to blood draws throughout the course of the study and venous access
             sufficient to allow for blood sampling as per the protocol;

          -  Must be negative for selected drugs of abuse at Screening and at Check-in (Day -1);

          -  Must have a negative hepatitis panel (including hepatitis B surface antigen [HBsAg]
             and hepatitis C virus antibody [HCV]) and negative human immunodeficiency virus [HIV]
             antibody screens;

          -  Females will be nonpregnant, nonlactating, and either postmenopausal, defined as
             amenorrhea for at least 1 year and follicle-stimulating hormone levels of 40 mIU/mL or
             higher; surgically sterile (eg, tubal ligation, hysterectomy, oophorectomy) for at
             least 90 days prior to Screening; or agree to use, from the time of signing the
             informed consent or 10 days prior to Check-in on Day -1 of the Inpatient Period until
             30 days after Study Discharge, one of the following forms of contraception:
             nonhormonal intrauterine device (IUD) with spermicide; female condom with spermicide;
             contraceptive sponge with spermicide; diaphragm with spermicide; cervical cap with
             spermicide; male sexual partner who agrees to use a male condom with spermicide; or
             sterile sexual partner; alternatively, women must agree to maintain abstinence (must
             agree to use a double barrier method if they become sexually active during the study.
             For all females of childbearing potential, the pregnancy test result must be negative
             at Screening and Check-in on Day -1 of the Inpatient Period (see Appendix 1). Women
             must also agree not to douche throughout the dosing period and until after the final
             visit;

          -  Males will either be sterile or agree to use, from Check-in on Day -1 of the Inpatient
             Period until 90 days following Study Discharge, one of the following approved methods
             of contraception: male condom with spermicide; sterile sexual partner; or use by
             female sexual partner of an IUD with spermicide; a female condom with spermicide; a
             contraceptive sponge with spermicide; an intravaginal system (eg, NuvaRingÂ®); a
             diaphragm with spermicide; a cervical cap with spermicide; or oral, implantable,
             transdermal, or injectable contraceptives. Subjects will refrain from sperm donation
             from Check-in on Day -1 of the Inpatient Period until 90 days following Study
             Discharge.

        Exclusion Criteria:

          -  Inability or unwillingness of a participant to give written informed consent or comply
             with study protocol;

          -  Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (eg, infectious disease) illness must
             not be enrolled into this trial;

          -  Presence of an uncontrolled, unstable clinically significant medical condition that in
             the opinion of the Investigator may increase the risk to the subject or may interfere
             with the interpretation of safety and PK evaluations, or could impair the subject's
             ability to complete the trial, or could impair the decisional capacity of the subject;

          -  Presence of clinically significant vital signs or a physical examination finding that,
             in the opinion of the Investigator, could increase the risk to the subject or may
             potentially interfere with the ability to evaluate safety and tolerability in the
             trial;

          -  History of tacrolimus use, or hypersensitivity and/or adverse reaction to calcineurin
             inhibitor drugs;

          -  History of toxic shock syndrome;

          -  Currently receiving chemotherapy or immunosuppressive agents;

          -  Use of investigative drugs within 30 days or 5 half-lives of study participation;

          -  Currently using sirolimus;

          -  Currently using live vaccines;

          -  Currently on concomitant substrates and/or inhibitors of CYP3A4;

          -  Requires the use of any concomitant medication, except for treatment of an adverse
             event (AE) during the study;

          -  Any abnormality on clinical laboratory tests, or ECG finding that is considered to be
             clinically significant by the Investigator.

          -  Known or suspected (nonfebrile) seizure disorder;

          -  Use of any other depot medications within the last three months.

          -  Unwilling to commit to avoid eating grapefruit or drinking grapefruit juice during the
             first 30 days of this exploratory study.

          -  Grade â¥ 1 finding as described in the Toxicity Grading Scale for Healthy Adult and
             Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George J Atiee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <results_first_submitted>May 20, 2019</results_first_submitted>
  <results_first_submitted_qc>May 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2019</results_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Immunosuppressant</keyword>
  <keyword>Sustained-release</keyword>
  <keyword>Plexis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03626714/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental: Sustained Release Injectable Tacrolimus</title>
          <description>All subjects will be treated with a single dose injection of sustained-release Tacrolimus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental: Sustained Release Injectable Tacrolimus</title>
          <description>All subjects will be treated with a single dose injection of sustained-release Tacrolimus.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.37" lower_limit="22" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects That Experienced Treatment-related Adverse Events [Safety and Tolerability]</title>
        <description>Adverse events were documented at each study visit according to the criteria set forth in the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials as follows:
Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening).</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Sustained Release Injectable Tacrolimus</title>
            <description>All subjects were subcutaneously injected a single dose (0.1 mg/kg) of sustained-release tacrolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Experienced Treatment-related Adverse Events [Safety and Tolerability]</title>
          <description>Adverse events were documented at each study visit according to the criteria set forth in the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials as follows:
Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness at Injection Site - Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning Pain at Injection Site - Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema/Redness at Injection Site - Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration/Swelling at Injection Site - Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at Injection Site - Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drug Concentrations in Blood Samples at Individual Time-points</title>
        <description>The concentrations of tacrolimus in blood samples were measured at baseline, day 1 (1 hr, 3 hrs, 6 hrs, 12 hrs, and 24 hrs), followed by days 3, 7, 14, 21, 30, 37, 44, 51 and 60.</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Sustained Release Injectable Tacrolimus</title>
            <description>All subjects were subcutaneously injected a single dose (0.1 mg/kg) of sustained-release tacrolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Concentrations in Blood Samples at Individual Time-points</title>
          <description>The concentrations of tacrolimus in blood samples were measured at baseline, day 1 (1 hr, 3 hrs, 6 hrs, 12 hrs, and 24 hrs), followed by days 3, 7, 14, 21, 30, 37, 44, 51 and 60.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.667" spread="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.956" spread="0.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="0.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.775" spread="0.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.341" spread="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.320" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.302" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.282" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.260" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.269" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.260" spread="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Blood Concentration-time Curve - Cmax</title>
        <description>Maximum observed tacrolimus whole blood concentration</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Sustained Release Injectable Tacrolimus</title>
            <description>All subjects were subcutaneously injected a single dose (0.1 mg/kg) of sustained-release tacrolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Concentration-time Curve - Cmax</title>
          <description>Maximum observed tacrolimus whole blood concentration</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Blood Concentration-time Curve - Tmax</title>
        <description>Time to maximum observed tacrolimus whole blood concentration</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Sustained Release Injectable Tacrolimus</title>
            <description>All subjects were subcutaneously injected a single dose (0.1 mg/kg) of sustained-release tacrolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Concentration-time Curve - Tmax</title>
          <description>Time to maximum observed tacrolimus whole blood concentration</description>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Concentration-time Curve [AUC]</title>
        <description>Area under the concentration-time curve</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Sustained Release Injectable Tacrolimus</title>
            <description>All subjects were subcutaneously injected a single dose (0.1 mg/kg) of sustained-release tacrolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Concentration-time Curve [AUC]</title>
          <description>Area under the concentration-time curve</description>
          <units>hour*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="568" spread="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life [t1/2]</title>
        <description>The apparent terminal elimination half-life was calculated.</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Sustained Release Injectable Tacrolimus</title>
            <description>All subjects were subcutaneously injected a single dose (0.1 mg/kg) of sustained-release tacrolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life [t1/2]</title>
          <description>The apparent terminal elimination half-life was calculated.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100" spread="803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For this single-dose experimental study, adverse event data was collected from subjects for up to 60 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental: Sustained Release Injectable Tacrolimus</title>
          <description>All subjects were subcutaneously injected a single dose (0.1 mg/kg) of sustained-release tacrolimus.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Decreased Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Decreased Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Alt/Ast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Elevated Aspartate</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Odontalgia left upper wisdom tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The studyâs main limitations include the small sample size (n=8) and the short duration (60 days).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sarjan Shah</name_or_title>
      <organization>Auritec</organization>
      <phone>9092109715</phone>
      <email>sshah@auritecpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

